Sonnet biotherapeutics announces pharmacokinetic and pharmacodynamic data in a phase 1 dose-escalation trial of son-1010
24 healthy volunteers have been dosed in study sb102 to assess the safety, pk, and pd of son-1010 without the background of prior chemotherapy pk data shows an extended half-life of son-1010 of approximately 112 hours, compared to 12 hours for rhil-12 simulation of the controlled and prolonged induction of ifng and minimal related adverse events suggest that dose escalation can continue princeton, nj / accesswire / january 19, 2023 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) (the "company" or "sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that pharmacokinetic (pk) profile simulation of son-1010 dosing has been completed in its randomized, placebo-controlled phase 1 clinical trial in healthy volunteers. historically, the therapeutic application of cytokines has been limited by relatively short half-lives and off-target toxicities that are typically associated with peak plasma levels.
SONN Ratings Summary
SONN Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission